Covaxin nod hasty or necessary 'backup'?  

As the row over Bharat Biotech's Covid vaccine Covaxin continues, the company's CMD Dr Krishan Ella today presented a point-by-point defence of the vaccine.

Addressing a press conference, Dr Ella slammed critics and said that the approvals have been granted on the basis of conditions set up by the Central Drugs Standard Control Organisation (CDSCO) 2019.

Experts and many politicians have questioned the approval to Covaxin in the absence of phase 3 clinical trial data.

So, is the nod to Covaxin given in haste? Should regulators have waited for phase 3 clinical trial data? Watch as panelists debate.